Sexually Transmitted Disease Modeling
Download
Report
Transcript Sexually Transmitted Disease Modeling
Predicting Human Papilloma
Virus Prevalence and Vaccine
Policy Effectiveness
Courtney Corley
Department of Computer Science
University of North Texas
June 27, 2005
Human Papilloma Virus
Sexually Transmitted Virus which can
lead to cervical dysplasia (cancer).
Found in 99.7%
of all cervical
cancers
June 27, 2005
Types
{16,18,31,45}
account for 75%
of cervical
cancer
Human Papilloma Virus
80% of the sexually active adult
population will contract HPV
U.S. spent over $1.6
billion in treating
symptoms of HPV
U.S. estimates
13,000 cases of
cervical cancer
2004
2005
June 27, 2005
$5-6 billion spent
on screening
tests such as pap
smears.
More than 5,000
will die from
cervical cancer
HPV Vaccine
Exciting news!
Several candidate vaccines are in phase III
testing with the FDA
Drug companies
are currently
in licensing
arbitration
June 27, 2005
Sexually Transmitted Disease Modeling
Sexual activity and sexually
active populations
Transmission Dynamics
• Contact rates and activity groups
• Risk of Transmission
Sexual mixing
• Demographic Stratification
June 27, 2005
Who do we model?
We model the
individuals who are
currently
sexually active
and able to contract the disease
June 27, 2005
Sexually Active
We define the
sexually active
population age
range as:
June 27, 2005
The range in years in which an individual
changes sexual partners more than
once per year on average
Sexually Active Ages
Given this concept of sexual activity the
age ranges for each model are:
HPV
15-30
15
0
30
20
June 27, 2005
40
Age (years)
Transmission Dynamics
Modeling sexually
transmitted diseases
is similar to
modeling other
infectious diseases,
they depend on:
June 27, 2005
Contact
Rates
Population
Mixing
Contact Rates
The contact-rate is the number of
partner changes per year
High
We define three
sexual activity
groups by
contact-rates:
Moderate
Low
June 27, 2005
Sexual Activity Groups
Population 100
100
80
60
High
Moderate
Low
People
40
20
0
1.5
3
9
Contact Rate
June 27, 2005
[partner changes/year]
Risk of Transmission
The risk of transmission is based on two
factors:
The risk of
transmission in
one sexual
encounter
June 27, 2005
The average number
of sexual
encounters with
one partner
Relative Risk of Transmission
The average is taken to determine the
relative risk for HPV infection:
HPV
Male-to-Female
Female-to-Male
June 27, 2005
80%
70%
Demographic Stratification
To accurately model geographic regions, we
categorize the population further:
Demographics
Age
June 27, 2005
Race
Demographic Stratification
We have our three activity groups:
Low
Moderate
High
And we have our
demographic parameters
Now we combine:
Age
Race
• a demographic trait
• the sexual activity classes
to represent the
June 27, 2005
demographically stratified population
Example Stratification
HPV
Age range 15-30 years
Stratify at 5 year intervals
Different contact rates can be assigned to each group
15-19
20-24
8
25-29
9
2.5
9.5
3.5
3
June 27, 2005
1
1.25
1.5
Population Interaction
A contact can take place between an individual in a
subgroup {demographic, sexual activity class}
and an individual
or
In the same subgroup
In a different subgroup
Consider our HPV population example:
15-19
20-24
9
8
1
9.5
3
2.5
June 27, 2005
25-29
1.25
3.5
1.5
Population Interaction Example
A 23 year old male in
the moderate
activity class will
make 3 contacts
per year
15-19
20-24
9
8
This is an example of where
the contacts could occur
June 27, 2005
9.5
3
2.5
1
25-29
1.25
3.5
1.5
So far . . .
Sexual Activity Classes
Demographic Stratification
Transmission Dynamics
• Contact Rates
• Population Interaction
June 27, 2005
Population States
Now, we need to keep track of
Who is susceptible to the disease
Who has the disease and is infectious
Who has recovered from the disease
Also for HPV
Who has been Vaccinated
Who has the disease and been vaccinated,
Vaccinated Infectious
June 27, 2005
HPV
Total Sexually Active Population
Susceptible
Vaccinated
Infectious
Vaccinated
Infectious
Recovered
Note: A constant population is
maintained. Every
year/update in the model a
proportion of the population
June 27, 2005
Enters or ages-in as susceptibles
Leaves or ages-out
Application
Our goal is to bridge the gap between
the mathematical epidemiologists and
professionals in industry and public
health officials
June 27, 2005
We have developed a computer
application interface to this
model, which simulates
endemic prevalence of a
disease
Application Interface
Input parameters:
Disease
Population
Vaccine
Output:
Populations in each
state over length of
simulation
June 27, 2005
HPV Application Demo
The following parameters are used in
this demo:
Age range 15-30, 5 year group interval
Sexual activity classes of low, moderate and high
Denton County, TX population data from the 2000 U.S.
Census
75% vaccine efficacy
90% vaccine coverage
Vaccine is effective for 10 years
June 27, 2005
Application Start Page
June 27, 2005
Input Parameters
June 27, 2005
Population Parameters
Denton County, 2000 U.S. Census Data
June 27, 2005
15-19
20-24
25-29
Total
Males
15,923
17,106
19,237
52,266
Females
15,579
18,478
19,193
53,250
Vaccine Parameters
June 27, 2005
Application Output
June 27, 2005
Population Graph Output
June 27, 2005
Population Ratio Graph Output
June 27, 2005
HPV Experiments
Vaccination Policy
Male (M)
Female (F)
Hughes, Garnett and Anderson Model
None
M&F
F
High-risk M & F
High-risk F
Spread targeting M & F
Spread targeting F
0.038
0.039
0.020
0.030
0.020
0.027
0.035
0.037
0.037
0.033
0.036
0.038
0.035
0.036
0.047
0.050
0.014
0.033
0.015
0.025
0.025
0.026
0.038
0.029
0.040
0.038
0.044
0.033
0.031
0.036
0.040
0.043
Temporal Model
None
M&F
F
Ages 15-19
Ages 15-19
Ages 20-24
Ages 20-24
Ages 25-29
Ages 25-29
June 27, 2005
M&F
F
M&F
F
M&F
F
Proportion of population
with sustained infection
Results
Qualitative assessment:
Denton County would have a larger
benefit in starting vaccination at age
(15-19) than vaccinating high-risk
minorities
June 27, 2005
Related Material
Our paper currently in review with the model description in the appendix:
http://cerl.unt.edu/~corley/pub/corley.ieee.bibe.2005.pdf
link to the web-application demo
http://cerl.unt.edu/~corley/hpv
June 27, 2005
Conclusion
Modeling these diseases with this
application will maximize resource
allocation and utilization in the
community or population where it is
most needed
June 27, 2005
References
Thank You!
J. Hughes and G. Garnett and L. Koutsky. The
Theoretical Population-Level Impact of a Prophylactic
Human Papilloma Virus Vaccine. Epidemiology,
13(6):631–639, November
2002.
N. Bailey. The Mathematical Theory of Epidemics.
Hafner Publishing Company, NY, USA, 1957.
R. Anderson and G. Garnett. Mathematical Models of
the Transmission and Control of Sexually Transmitted
Diseases. Sexually Transmitted Diseases,
27(10):636–643, November 2000.
S. Goldie and M. Kohli and D. Grima. Projected Clinical
Benefits and Cost-effectiveness of a Human
Papillomavirus 16/18 Vaccine. National Cancer
Institute, 96(8):604–615, April 2004.
The Youth Risk Behaviour Website, Centers for
Disease Control and Prevention, 2005.
http://www.cdc.gov/HealthyYouth/yrbs
M. Katz and J. Gerberding. Postexposure Treatment of
People Exposed to the Human Immunodeficiency
Virus through Sexual Contact or Injection-Drug Use.
New England Journal of Medicine, 336:1097-1100,
April 1997.
June 27, 2005
Youth Risk Behaviour Surveillance: National College
Health Risk Behaviour Survey, Centers for Disease
Control and Prevention, 1995.
D. Heymann and G. Rodier. Global Surveillance,
National Surveillance, and SARS. Emerging Infectious
Diseases, 10(2), February 2004.
E. Allman and J. Rhodes. Mathematical Models in
Biology: An Introduction. Cambridge University Press,
2004.
G. Garnett and R. Anderson. Contact Tracing and the
Estimation of Sexual Mixing Patterns: The
Epidemiology of Gonococcal Infections. Sexually
Transmitted Diseases, 20(4):181–191, July-August
1993.
G. Sanders and A. Taira. Cost Effectiveness of a
Potential Vaccine for Human Papillomavirus. Emerging
Infectious Diseases, 9(1):37–48, January 2003.
J. Aron. Mathematical Modelling: The Dynamics of
Infection, chapter 6. Aspen Publishers, Gaithersburg,
MD, 2000.